You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
業聚醫療(06929.HK)預計12月23日上市 引入富陽產業基金投資管理作為基石
格隆匯 12-13 06:30

格隆匯12月13日丨業聚醫療(06929.HK)發佈公吿,公司擬全球發售5463.3萬股股份,其中中國香港發售股份546.4萬股,國際發售股份4916.9萬股;2022年12月13日至12月16日招股;發售價為每股發售股份8.80港元,每手買賣單位500股,入場費約4444.3港元;中金公司及建銀國際為聯席保薦人;預期股份將於2022年12月23日於聯交所主板掛牌上市。

集團是一家專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商。PCI及PTA市場屬規模小且集中的專營市場。公司總部設於中國香港,集團的產品不但銷往全球逾70個國家和地區,集團也是唯一一家總部設在中國,且在包括日本、歐洲及美國在內的所有主要海外PCI球囊市場排名前六的公司。除PCI/PTA球囊外,集團亦專攻冠狀動脈支架產品,並積極將集團的業務擴展至神經血管介入及結構性心臟病領域。

集團、聯席保薦人及整體協調人已與基石投資者(即杭州富陽產業基金投資管理有限公司)訂立基石投資協議,據此,基石投資者已同意,在若干條件的規限下,按發售價認購總金額為3.14億港元可供購買的一定數目的發售股份。基石投資者將按發售價8.80港元認購的發售股份總數將為3568.15萬股發售股份,相當於全球發售項下發售股份的約65.31%及緊隨全球發售完成後集團已發行股本總額的約4.31%。

按發售價每股8.80港元計算,集團估計將收取所得款項淨額約3.668億港元。集團擬將自全球發售收取的所得款項淨額30.0%分配予集團的在研產品開發及商業化,而使用該等所得款項的分配及預期時間表將取決於相應研發項目的時間、進度及規模,以及計及集團產品組合的持續擴張後,集團預期的研發及臨牀試驗相關開支;54.2%被分配用於擴大集團的產能;10.8%用於為潛在戰略收購、建立戰略合作伙伴關係及其他業務發展提供資金,旨在擴大集團的產品組合、增強集團的研發能力、擴大集團的醫院覆蓋範圍及提高集團的市場滲透率;以及所得款項淨額的5.0%用作營運資金及用於其他一般企業事項。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account